bioAffinity Technologies, Inc. BIAF revenue by segment, product and geography
In its fiscal year ending 2025-12-31, bioAffinity Technologies, Inc. reported revenue across 7 products and services; the largest, Laboratory Services, was $6.16M (-34.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Laboratory Services$6.16Mshare n/a-34.1% yoy
- Health Care Patient Service$4.97Mshare n/a-39.2% yoy
- Histology Service Fees$1.12Mshare n/a+1.2% yoy
- Medical Director Fees$68.3Kshare n/a+2.5% yoy
- Other Revenues$4.86Kshare n/a-34.1% yoy
- Diagnostic Research And Development$577share n/a-93.3% yoy
- Department Of Defense Observational Studies$577share n/a-93.3% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- General Corporate Activities-$7.69M46.0%+16.8% yoy
- Laboratory Services-$6.95M41.5%-30.1% yoy
- Diagnostic Research And Development-$2.09M12.5%+17.2% yoy
Members sum to -$16.7M against -$10.6M consolidated (residual $6.16M) - eliminations or corporate lines the filer did not tag on this axis.
- Laboratory Services$1.51Mshare n/a+19.0% yoy
- Health Care Patient Service$1.24Mshare n/a+32.1% yoy
- Histology Service Fees$248Kshare n/a-19.6% yoy
- Medical Director Fees$17.5Kshare n/a+1.4% yoy
- Other Revenues$633share n/a-57.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.